Anticoagulation for Stroke Prevention
Cardioembolic stroke is a devastating condition, with high mortality and a high rate of disability amongst survivors.
Anticoagulation, a highly effective preventive intervention is under-utilised, leading to an estimated 7000 preventable strokes in the UK annually.
There is a drive to increase screening for AF in primary care, which should be supplemented by response to identified AF in hospitalised patients.
Newer licensed options for anticoagulation have practical advantages over warfarin, which may allow an increase in the rate and consistency of anticoagulation, and consequently lower stroke rates.
We will discuss the developing recent evidence regarding the newer agents, their benefits and limitations, leading on to, I hope, a lively debate.
This webinar is to inform and educate interventional cardiologists and cardiac surgeons on:
- The characteristics of AF-associated stroke
- The missed opportunity for 7000 people every year whose stroke could have been prevented by anticoagulation
- The Oral Direct Inhibitors (ODI), which afford alternatives to warfarin
- The myths and realities about ODI
This webinar is aimed at:
- Stroke Physicians
- Primary Care Physicians
University Hospitals of Leicester NHS Trust, UK
1. ROCKET AF study
2. RELY study
3. ARISTOLE study
4. AVERROES study
5. NICE TA 249 Dabigatran for AF
6. NICE TA 256 Rivaroxaban for AF
7. NICE TA 275 Apixaban for AF